BRAINSTORM CELL THERAPEUTICS INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following documents are filed as exhibits to this report:
| | | | | | | Incorporated by Reference Herein | | ||||
| ExhibitNumber | Description | Filed (or Furnished) with this Form 10-Q | Form | Exhibit & File No. | Date Filed | ||||||
| | | | | | | | | | | | |
| 3.1 | | Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. | | | | Definitive Schedule 14A | | Appendix B File No. 333-61610 | | November 20, 2006 | |
| 3.2 | | Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 15, 2014. | | | | Form 8-K | | Exhibit 3.1 File No. 000-54365 | | September 16, 2014 | |
| 3.3 | | Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated August 31, 2015. | | | | Form 8-K | | Exhibit 3.1 File No. 001-366641 | | September 4, 2015 | |
| 3.4 | | ByLaws of Brainstorm Cell Therapeutics Inc. | | | | Definitive Schedule 14A | | Appendix C File No. 333-61610 | | November 20, 2006 | |
| 3.5 | | Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007. | | | | Form 8-K | | Exhibit 3.1 File No. 333-61610 | | March 27, 2007 | |
| 4.1 | | Form of Warrant | | * | | | | | | | |
| 4.2 | | Form of Pre-Funded Warrant | | | | Form 8-K | | Exhibit 4.2 File No. 001 -36641 | | June 28, 2024 | |
| 10.1¥ | | Employment Agreement dated June 19, 2024 between Brainstorm Cell Therapeutics Inc. and Hartoun Hartounian | | * | | | | | | | |
| 10.2¥ | | Separation Agreement dated April 16, 2024 between Brainstorm Cell Therapeutics Inc. and Stacy Lindborg | | * | | | | | | | |
| 10.3 | | Form of Securities Purchase Agreement dated June 27, 2024 between Brainstorm Cell Therapeutics Inc. and the purchaser party thereto | | | | Form 8-K | | Exhibit 10.1 File No. 001 -36641 | | June 28, 2024 | |
| 10.4 | | Placement Agency Agreement, dated as of June 27, 2024 by and between Brainstorm Cell Therapeutics Inc. and the placement agent party thereto. | | | | Form 8-K | | Exhibit 10.2 File No. 001 -36641 | | June 28, 2024 | |
| 10.5 | | Form of Warrant Amendment Agreement, dated June 27, 2024 between the Company and the purchaser party thereto | | | | Form 8-K | | Exhibit 10.3 File No. 001 -36641 | | June 28, 2024 | |
| 10.6 | | Amendment No. 1 dated April 2, 2024 to the Distribution Agreement dated August 9, 2024 by and among Brainstorm Cell Therapeutics Inc., Leerink Partners LLC and Raymond James & Associates, Inc. | | | | Form 8-K | | Exhibit 1.1 File No. 001 -36641 | | April 2, 2024 | |
| 10.7 | | Restricted Stock Agreement dated as of June 3, 2024 under the 2014 Global Share Option Plan between Brainstorm Cell Therapeutics Inc. and Chaim Lebovits | | * | | | | | | | |
| 10.8 | | Restricted Stock Agreement dated as of May 2, 2024 under the 2014 Stock Incentive Plan between Brainstorm Cell Therapeutics Inc. and Stacy Lindborg | | * | | | | | | | |
| 10.9 | | Restricted Stock Agreement dated as of April 21, 2024 under the 2014 Global Share Option Plan between Brainstorm Cell Therapeutics Inc. and Alla Patlis | | * | | | | | | | |
| 10.10 | | Restricted Stock Agreement dated as of April 7, 2024 under the 2014 Global Share Option Plan between Brainstorm Cell Therapeutics Inc. and Uri Yablonka | | * | | | | | | | |
| 31.1 | | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | * | | | | | | | |
| 31.2 | | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | * | | | | | | | |
| 32.1 | | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | ‡ | | | | | | | |
| 32.2 | | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | ‡ | | | | | | | |
| 101.INS | | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | | * | | | | | | | |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document | | * | | | | | | | |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | * | | | | | | | |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | * | | | | | | | |
| 101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document | | * | | | | | | | |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | * | | | | | | | |
| 104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | | * | | | | | | | |
*Filed herewith
‡Furnished herewith
#Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission upon request.
¥Indicates a management contract or any compensatory plan, contract or arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.